Commune · Savoirs
Tabernanthalog
Chemical compound
Tabernanthalog (TBG; developmental code name DLX-007) is a non-selective serotonin receptor modulator and putatively non-psychedelic psychoplastogen of the ibogalog group related to the iboga alkaloid tabernanthine but with a simplified chemical structure. It was developed by David E. Olson and colleagues at the University of California, Davis.
Sur Wikipédia
Texte en anglais Pas encore d'article dans ta langue : extrait en anglais.
Tabernanthalog (TBG; developmental code name DLX-007) is a non-selective serotonin receptor modulator and putatively non-psychedelic psychoplastogen of the ibogalog group related to the iboga alkaloid tabernanthine but with a simplified chemical structure. It was developed by David E. Olson and colleagues at the University of California, Davis. The drug is being developed by Delix Therapeutics as a potential pharmaceutical drug for treatment of neuropsychiatric disorders. However, as of January 2026, tabernanthalog has still yet to enter clinical trials.
Texte : Wikipédia en anglais, CC BY-SA 4.0. · Image : Jovan Gec (CC BY-SA 4.0) ·
